Immunotherapy regimens including anti-programmed cell death protein 1 (PD-1) or anti-programmed cell death ligand 1 (PD-L1) agents are widely used in patients with resectable stage II-III non-small cell lung cancer (NSCLC) who do not harbor epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alterations, or patients with unresectable stage III EGFR-wild type NSCLC after chemoradiotherapy completion [2]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.